WO1999048507A3 - Steroidal saponins for treating alzheimer's disease - Google Patents

Steroidal saponins for treating alzheimer's disease Download PDF

Info

Publication number
WO1999048507A3
WO1999048507A3 PCT/GB1999/000951 GB9900951W WO9948507A3 WO 1999048507 A3 WO1999048507 A3 WO 1999048507A3 GB 9900951 W GB9900951 W GB 9900951W WO 9948507 A3 WO9948507 A3 WO 9948507A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
treating alzheimer
steroidal saponins
saponins
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/000951
Other languages
French (fr)
Other versions
WO1999048507A2 (en
Inventor
Zongqin Xia
Yaer Hu
Ian Rubin
Jonathan Brostoff
Brian Whittle
Weijun Wang
Phil Gunning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytopharm Ltd
Original Assignee
Phytopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806513.9A external-priority patent/GB9806513D0/en
Priority claimed from GBGB9905275.5A external-priority patent/GB9905275D0/en
Priority to NZ507355A priority Critical patent/NZ507355A/en
Priority to DE69933016T priority patent/DE69933016T2/en
Priority to HR20000638A priority patent/HRP20000638A2/en
Priority to PL380866A priority patent/PL207723B1/en
Priority to JP2000537555A priority patent/JP3768100B2/en
Priority to PL99343423A priority patent/PL195897B1/en
Priority to HU0101693A priority patent/HUP0101693A3/en
Priority to EP99913453A priority patent/EP1066042B1/en
Priority to BR9909109-7A priority patent/BR9909109A/en
Priority to IL13866399A priority patent/IL138663A0/en
Priority to CA002325633A priority patent/CA2325633C/en
Priority to AU31574/99A priority patent/AU748138B2/en
Priority to HK01104373.8A priority patent/HK1033903B/en
Application filed by Phytopharm Ltd filed Critical Phytopharm Ltd
Publication of WO1999048507A2 publication Critical patent/WO1999048507A2/en
Publication of WO1999048507A3 publication Critical patent/WO1999048507A3/en
Priority to IL138663A priority patent/IL138663A/en
Priority to IS5637A priority patent/IS5637A/en
Priority to NO20004804A priority patent/NO20004804L/en
Anticipated expiration legal-status Critical
Priority to US10/077,493 priority patent/US6812213B2/en
Priority to US10/109,095 priority patent/US7138427B2/en
Priority to US11/346,046 priority patent/US20060165757A1/en
Priority to IL174991A priority patent/IL174991A0/en
Priority to US11/502,784 priority patent/US7507720B2/en
Priority to CY20061101448T priority patent/CY1105653T1/en
Priority to US11/894,105 priority patent/US20080020021A1/en
Priority to NO20083993A priority patent/NO20083993L/en
Priority to NO20085251A priority patent/NO20085251L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

The invention discloses the use of a number of saponins and sapogenins, notably those of steroidal structure, in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are also disclosed.
PCT/GB1999/000951 1998-03-26 1999-03-26 Steroidal saponins for treating alzheimer's disease Ceased WO1999048507A2 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
BR9909109-7A BR9909109A (en) 1998-03-26 1999-03-26 Uses of one or more among smilagenin, pleasedigenin, an astragaloside, tigogenin, ruscogenin, hecogenin, diogenin, smilagenin, anzurogenin d or an astragaloside and an extract from a plant of the genus smilax, asparagus, anemarrhena, yucca, yucca or yucca. for the treatment of a condition distinguished by a deficiency in the function or the number of membrane-bound postsynaptic receptors, pharmaceutical composition, and, processes to enhance cognitive function in a human or non-human animal and in a patient suffering from an age-related cognitive impairment, and to treat a condition distinguished by a deficiency in function or the number of membrane-bound receptors in a tissue, organ, cell type or organelle
HK01104373.8A HK1033903B (en) 1998-03-26 1999-03-26 Steroidal saponins for treating alzheimer's disease
IL13866399A IL138663A0 (en) 1998-03-26 1999-03-26 Steroidal sapogenins and their derivatives for treating alzheimer's disease
HR20000638A HRP20000638A2 (en) 1998-03-26 1999-03-26 Steroidal sapogenins and their derivatives for treating alzheimer's disease
PL380866A PL207723B1 (en) 1998-03-26 1999-03-26 Steroid sapogenins and their derivatives intended for treating Alzheimer disease
JP2000537555A JP3768100B2 (en) 1998-03-26 1999-03-26 Steroid sapogenins and their derivatives for the treatment of Alzheimer's disease
PL99343423A PL195897B1 (en) 1998-03-26 1999-03-26 Membrane-bound receptors and their function; cognitive disfunction; treatments therefor; and compositions for use in such treatments
HU0101693A HUP0101693A3 (en) 1998-03-26 1999-03-26 Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease
EP99913453A EP1066042B1 (en) 1998-03-26 1999-03-26 Steroidal saponins for treating alzheimer's disease
NZ507355A NZ507355A (en) 1998-03-26 1999-03-26 Membrane-bound receptors and their function; cognitive disfunction; treatments therefor; and compositions for use in such treatments
DE69933016T DE69933016T2 (en) 1998-03-26 1999-03-26 STEROIDAL SAPONINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CA002325633A CA2325633C (en) 1998-03-26 1999-03-26 Steroidal sapogenins and their derivatives for treating alzheimer's disease
AU31574/99A AU748138B2 (en) 1998-03-26 1999-03-26 Steroidal sapogenins and their derivatives for treating alzheimers disease
IL138663A IL138663A (en) 1998-03-26 2000-09-24 Steroidal sapogenins and their derivatives for treating alzheimer's disease
IS5637A IS5637A (en) 1998-03-26 2000-09-25 Steroid sapogenins and their derivatives for the treatment of Alzheimer's disease
NO20004804A NO20004804L (en) 1998-03-26 2000-09-26 Steroid sapogenes and their derivatives for the treatment of Alzheimer's disease
US10/077,493 US6812213B2 (en) 1998-03-26 2002-02-15 Steroidal sapogenins and their derivatives for treating alzheimer's disease
US10/109,095 US7138427B2 (en) 1999-03-26 2002-03-28 5-β-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
US11/346,046 US20060165757A1 (en) 1999-03-26 2006-02-02 5-hydroxysapogenin derivatives with anti-dementia activity
IL174991A IL174991A0 (en) 1998-03-26 2006-04-11 Steroidal sapogenins and their derivatives for treating alzheimer's disease
US11/502,784 US7507720B2 (en) 1998-03-26 2006-08-11 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
CY20061101448T CY1105653T1 (en) 1998-03-26 2006-10-10 Steroidal saponins for the treatment of ALZHEIMER'S DISEASE
US11/894,105 US20080020021A1 (en) 1999-03-26 2007-08-20 5-Hydroxysapogenin derivatives with anti-dementia activity
NO20083993A NO20083993L (en) 1998-03-26 2008-09-19 Use of sarsasapogenin and smilagenin in the preparation of medications
NO20085251A NO20085251L (en) 1998-03-26 2008-12-16 Steroid sapogenes and their derivatives for the treatment of Alzheimer's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9806513.9 1998-03-26
GBGB9806513.9A GB9806513D0 (en) 1998-03-26 1998-03-26 Membrane-bound receptors
GBGB9905275.5A GB9905275D0 (en) 1999-03-08 1999-03-08 Treatment of conditions associated with membrane-bound receptors and their function
GB9905275.5 1999-03-08

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US09647110 A-371-Of-International 1999-03-26
PCT/GB2000/003737 Continuation-In-Part WO2001023406A1 (en) 1998-03-26 2000-09-29 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
PCT/GB2000/003750 Continuation-In-Part WO2001023408A1 (en) 1999-03-26 2000-09-29 5-hydroxysapogenin derivatives with anti-dementia activity
US10/108,737 Continuation US20030100542A1 (en) 1999-03-26 2002-03-28 5-hydroxysapogenin derivatives with anti-dementia activity

Publications (2)

Publication Number Publication Date
WO1999048507A2 WO1999048507A2 (en) 1999-09-30
WO1999048507A3 true WO1999048507A3 (en) 1999-11-25

Family

ID=26313369

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1999/000960 Ceased WO1999048482A2 (en) 1998-03-26 1999-03-26 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
PCT/GB1999/000951 Ceased WO1999048507A2 (en) 1998-03-26 1999-03-26 Steroidal saponins for treating alzheimer's disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000960 Ceased WO1999048482A2 (en) 1998-03-26 1999-03-26 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease

Country Status (27)

Country Link
US (2) US6812213B2 (en)
EP (3) EP1066033B1 (en)
JP (4) JP3768100B2 (en)
KR (6) KR20090009997A (en)
CN (3) CN1198622C (en)
AT (3) ATE337788T1 (en)
AU (2) AU748138B2 (en)
BR (2) BR9909109A (en)
CA (2) CA2325634A1 (en)
CY (1) CY1105653T1 (en)
DE (3) DE69943415D1 (en)
DK (2) DK1066042T3 (en)
ES (2) ES2257042T3 (en)
GB (1) GB2335599B (en)
HR (2) HRP20000638A2 (en)
HU (2) HUP0103654A2 (en)
ID (2) ID26781A (en)
IL (4) IL138663A0 (en)
IS (2) IS5637A (en)
MX (1) MXPA00009437A (en)
NO (4) NO20004804L (en)
NZ (1) NZ507355A (en)
PL (3) PL195897B1 (en)
PT (1) PT1066042E (en)
RU (1) RU2297228C2 (en)
TR (2) TR200002774T2 (en)
WO (2) WO1999048482A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277978B1 (en) 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US20030118673A1 (en) * 1998-03-26 2003-06-26 Zongqin Xia Smilagenin and anzurogenin-D for the treatment of alzheimer's disease
PL195897B1 (en) * 1998-03-26 2007-11-30 Phytopharm Plc Membrane-bound receptors and their function; cognitive disfunction; treatments therefor; and compositions for use in such treatments
AU781810B2 (en) * 1998-03-26 2005-06-16 Phytopharm Plc. Steroidal sapogenins and their derivatives for treating Alzheimer's disease
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
DE60326437D1 (en) * 2002-03-27 2009-04-16 Phytopharm Plc Godmanchester THERAPEUTIC USE OF SAPOGENINES
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
JP4573157B2 (en) * 2002-03-27 2010-11-04 フィトファーム・パブリック・リミテッド・カンパニー Method of treatment and use of sapogenin and its derivatives
KR20100093621A (en) * 2002-03-27 2010-08-25 파이토팜 피엘씨 Theraputic methods and uses of sapogenin and their derivatives
CN102727501A (en) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 Uses of saponins and derivatives thereof
PL210114B1 (en) 2002-10-28 2011-12-30 Phytopharm Plc Stereospecific reduction of sapogen-3-ones
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0409567D0 (en) * 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
AU2005295617A1 (en) * 2004-10-14 2006-04-27 Georgetown University Neuroprotective spirostenol pharmaceutical compositions
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
KR100779179B1 (en) * 2006-05-19 2007-11-28 충북대학교 산학협력단 Cerebral nerve protection or degenerative brain disease prevention or treatment containing methanol extract of Rhobok-ryeong
JP2009256243A (en) * 2008-04-17 2009-11-05 Noevir Co Ltd Humectant, antiaging agent, antioxidant, skin care preparation and functional oral composition
US8217165B2 (en) 2008-06-17 2012-07-10 Pawan Kumar Goel Process for the extraction of furostanolic saponins from fenugreek seeds
KR101027384B1 (en) * 2009-06-29 2011-04-11 에이디엠이십일 주식회사 Connecting device of flat wiper blade and wiper arm
WO2010084356A1 (en) 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
AU2011281336B2 (en) 2010-07-20 2015-03-05 Junaxo, Inc. Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders
TWI422378B (en) * 2010-11-18 2014-01-11 Univ Chung Shan Medical Improvement of cognitive deficit associated with menopausal syndrome with diosgenin
CN102389438A (en) * 2011-06-30 2012-03-28 北京师范大学 Application of Astragaloside IV
WO2014112145A1 (en) * 2013-01-21 2014-07-24 レジリオ株式会社 Therapeutic agent and therapeutic method relating to 1,25d3-marrs for neurological disease such as alzheimer's disease
CN107250340B (en) 2014-09-16 2021-05-07 罗伯特·布洛西亚 Energy drinks and other nutritional aids derived from agave-based spirits
KR101777920B1 (en) * 2015-07-27 2017-09-14 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 The composition containing ginsenoside F1 for removing amyloid plaques
CN105168785A (en) * 2015-10-08 2015-12-23 湖北民族学院 Traditional Chinese medicine preparation for treating AD (Alzheimer's disease) and preparation method
EP3572085A1 (en) * 2018-05-25 2019-11-27 Neuro-Sys Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN108514603B (en) * 2018-06-28 2021-12-28 佳木斯大学 Traditional Chinese medicine composition for treating rigid Parkinson's disease and preparation method thereof
KR102028730B1 (en) 2019-05-22 2019-10-04 (주)클래시스 Method for preparing anemarrhena asphodeloides extract using focused ultrasonic treatment, and anemarrhena asphodeloides extract obtained therefrom
CN110859849A (en) * 2019-12-11 2020-03-06 大连医科大学 Application of dioscin in preparation of Parkinson disease protection medicine
US11788574B2 (en) 2021-08-13 2023-10-17 Rimgard Sweden AB Anti-theft locking bolt assembly

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4303214A1 (en) * 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
CN1096031A (en) * 1993-05-31 1994-12-07 上海第二医科大学 The medicine and the method for making thereof that beta-2 adrenoceptor and M cholinocepter are had dual regulation
WO1999016786A1 (en) * 1997-09-26 1999-04-08 Institute Of Radiation Medicine, Academy Of Military Medical Sciences Of The Pla The use of steroid saponin compounds to prevent senility, and novel steroid saponin compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794362A (en) * 1972-01-22 1973-07-23 Merck Patent Gmbh WATER-SOLUBLE STERINE SULPHATES
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (en) * 1974-04-08 1975-10-09 Degussa MEDICINAL PRODUCTS WITH THE MAIN APOGNANT OF THE HELLEBORUS SPECIES AS THE ACTIVE SUBSTANCE
LU81256A1 (en) 1979-05-15 1980-12-16 Oreal HAIR COSMETIC COMPOSITION, IN PARTICULAR FOR WASHING AND / OR UNMAKING HAIR, BASED ON AN EXTRACT OF PLANTS CONTAINING SAPONOSIDES
JPS5855500A (en) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk Preparation of 16-dehydropregnenolone
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (en) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh MEDICINAL PRODUCTION OF ESTER DERIVATIVES OF HECOGENINE AND ITS USE FOR THE TREATMENT OF BENIGNER PROSTATE HYPERPLASIA
WO1991010743A1 (en) * 1990-01-18 1991-07-25 Cura Nominees Pty Ltd Glycoalkaloids
DE4122706C1 (en) * 1991-07-09 1993-03-04 Steigerwald Arzneimittelwerk
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
US5629295A (en) * 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
WO1994018994A1 (en) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Therapeutic herbal composition
CN1092992A (en) * 1993-03-29 1994-10-05 中国科学院沈阳应用生态研究所 Improve medicine of brain function and preparation method thereof
CN1052636C (en) * 1993-03-29 2000-05-24 中国科学院沈阳应用生态研究所 Application of Alcoholic Extract of Radix Xanthana Fruit in Preparation of Medicine for Mental Retardation
CA2161239A1 (en) * 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl glycosidal crystalline monohydrate
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
EP0737202A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Hypocholesterolemic agents
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
FI970828L (en) * 1994-08-30 1997-02-27 Pfizer Spirostanyl glycoside crystals
AU2453295A (en) * 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
WO1996038466A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Steroidal glycosides
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5804239A (en) 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
KR20010023208A (en) * 1997-08-28 2001-03-26 브루스, 제임스 에이취 Chemical and Pharmacological Standardization of Herbal Extracts
JP3873097B2 (en) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 Anti-obesity agent and lipid metabolism improving agent
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
PL195897B1 (en) * 1998-03-26 2007-11-30 Phytopharm Plc Membrane-bound receptors and their function; cognitive disfunction; treatments therefor; and compositions for use in such treatments
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4303214A1 (en) * 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
CN1096031A (en) * 1993-05-31 1994-12-07 上海第二医科大学 The medicine and the method for making thereof that beta-2 adrenoceptor and M cholinocepter are had dual regulation
WO1999016786A1 (en) * 1997-09-26 1999-04-08 Institute Of Radiation Medicine, Academy Of Military Medical Sciences Of The Pla The use of steroid saponin compounds to prevent senility, and novel steroid saponin compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G. BLUDEN ET AL.: "Steroidal sapogenins from leaves of Agaveae species", STN INTERNATIONAL. FILE BIOSIS. AN=1979:172390, XP002117142 *
N. YI ET AL.: "Sarsasapogenin: Mechanism in treating senile dementia", PROCEEDINGS OF THE SIXTH INTERNATIONAL SYMPOSIUM OF THE INTERNATIONAL ISOTOPE SOCIETY, PHILADELPHIA, 1997, pages 315 - 320, XP002117140 *
STN INTERNATIONAL. FILE CHEMICAL ABSTRACTS. AN=123:266081, XP002117141 *

Also Published As

Publication number Publication date
PL343423A1 (en) 2001-08-13
BR9909109A (en) 2000-12-12
TR200002773T2 (en) 2001-11-21
ES2272060T3 (en) 2007-04-16
DE69933016T2 (en) 2007-03-29
ID26781A (en) 2001-02-08
ID26989A (en) 2001-02-22
US20020193317A1 (en) 2002-12-19
DK1719512T3 (en) 2011-08-15
CN1209112C (en) 2005-07-06
KR20070117001A (en) 2007-12-11
EP1719512A2 (en) 2006-11-08
PL207723B1 (en) 2011-01-31
JP2002507572A (en) 2002-03-12
TR200002774T2 (en) 2001-06-21
EP1066042B1 (en) 2006-08-30
AU748138B2 (en) 2002-05-30
HUP0101693A3 (en) 2002-08-28
MXPA00009437A (en) 2002-05-06
CN1301166A (en) 2001-06-27
EP1066033A1 (en) 2001-01-10
IL138663A0 (en) 2001-10-31
RU2297228C2 (en) 2007-04-20
GB2335599B (en) 2001-08-01
CN1198622C (en) 2005-04-27
KR101092050B1 (en) 2011-12-12
CY1105653T1 (en) 2010-12-22
CN100377714C (en) 2008-04-02
KR100632052B1 (en) 2006-10-04
BR9909110A (en) 2000-12-12
GB2335599A (en) 1999-09-29
ATE507834T1 (en) 2011-05-15
WO1999048482A2 (en) 1999-09-30
EP1066042A2 (en) 2001-01-10
HK1033903A1 (en) 2001-10-05
KR20070007214A (en) 2007-01-12
DK1066042T3 (en) 2006-12-18
DE69933016D1 (en) 2006-10-12
EP1066033B1 (en) 2005-12-28
EP1719512A3 (en) 2007-04-11
PL380866A1 (en) 2001-08-13
PT1066042E (en) 2006-12-29
US6812213B2 (en) 2004-11-02
EP1719512B1 (en) 2011-05-04
DE69943415D1 (en) 2011-06-16
NZ507355A (en) 2004-02-27
ATE337788T1 (en) 2006-09-15
CA2325634A1 (en) 1999-09-30
KR20010042205A (en) 2001-05-25
CN1679591A (en) 2005-10-12
IL138663A (en) 2006-08-01
US20060182817A1 (en) 2006-08-17
CA2325633C (en) 2009-01-20
NO20083993L (en) 2000-09-11
NO20004804D0 (en) 2000-09-26
CN1302208A (en) 2001-07-04
NO20085251L (en) 2000-11-09
HRP20000638A2 (en) 2001-04-30
GB9907100D0 (en) 1999-05-19
IS5638A (en) 2000-09-25
IL138664A0 (en) 2001-10-31
WO1999048482A3 (en) 2000-11-23
IL174991A0 (en) 2006-08-20
KR20090007505A (en) 2009-01-16
HRP20000637A2 (en) 2001-04-30
NO20004803L (en) 2000-11-27
JP2004224797A (en) 2004-08-12
HK1033742A1 (en) 2001-09-21
PL195897B1 (en) 2007-11-30
RU2004123463A (en) 2006-01-27
HK1091417A1 (en) 2007-01-19
JP3768100B2 (en) 2006-04-19
KR100713311B1 (en) 2007-05-04
IS5637A (en) 2000-09-25
ATE314057T1 (en) 2006-01-15
NO20004804L (en) 2000-11-09
AU3157499A (en) 1999-10-18
HUP0101693A2 (en) 2001-12-28
HUP0103654A2 (en) 2002-02-28
NO20004803D0 (en) 2000-09-26
JP2003524581A (en) 2003-08-19
PL343508A1 (en) 2001-08-27
DE69929177T2 (en) 2006-08-24
DE69929177D1 (en) 2006-02-02
CA2325633A1 (en) 1999-09-30
KR20010042190A (en) 2001-05-25
WO1999048507A2 (en) 1999-09-30
AU3158199A (en) 1999-10-18
JP2004217666A (en) 2004-08-05
ES2257042T3 (en) 2006-07-16
KR20090009997A (en) 2009-01-23

Similar Documents

Publication Publication Date Title
WO1999048507A3 (en) Steroidal saponins for treating alzheimer's disease
WO2001049703A3 (en) Substituted sapogenins and their use
CA2385410A1 (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction
CA2284170A1 (en) Identification of agents for use in the treatment of alzheimer's disease
GB9923076D0 (en) Sapogenin derivatives and their use
IL141507A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
CA2347863A1 (en) Treatment of disorders of the outer retina
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
GB9923078D0 (en) Sapogenin derivatives and their use
HUP9702480A3 (en) New polymorphous form of doxazosin-mesylate (form. i.), process for it's preparation and pharmaceutical compositions containing the same
HUP9702479A3 (en) New polymorphous form of doxazosin-mesylate (form ii.), process for it's preparation and pharmaceutical compositions containing the same
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
ZA200006046B (en) Steroidal sapogenins and their derivatives for treating Alzheimer's disease.
AU2215099A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
ZA200102029B (en) Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99806158.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 138663

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2325633

Country of ref document: CA

Ref document number: 2325633

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2000-3541

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009441

Country of ref document: MX

Ref document number: P20000638A

Country of ref document: HR

Ref document number: 2000/02774

Country of ref document: TR

Ref document number: 1020007010677

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 507355

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 31574/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999913453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200006046

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/543/CHE

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1999913453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09647110

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-3541

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007010677

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-3541

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 31574/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007010677

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1999913453

Country of ref document: EP